Novo Nordisk's new obesity drug hits 8,000-prescription mark in few weeks: Comparing with Saxenda, it took around four years — MedWatch
FDA Approves NDA for Novo Nordisk's Weight Loss Injectable Saxenda – Obesity News Today
Prescription Weight-Loss Medicine | Saxenda® (liraglutide) injection 3mg
Positive new trial results for obesity treatment Saxenda in early resp
FDA approves Novo Nordisk Obesity Drug Saxenda • NCK Pharma
Effective obesity management: It's more than reducing numbers on the scale
Savings & Support | NovoCare®
![Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management](http://photos.prnewswire.com/prnfull/20141224/166096 "Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management")
Novo Nordisk receives FDA approval for Saxenda® (liraglutide [rDNA origin] injection) for chronic weight management
Saxenda® (liraglutide) injection 3mg Savings Card | NovoCare®
NICE recommends new treatment from Novo Nordisk for obesity
How to Use the Saxenda® (liraglutide) Injection 3 mg Pen
Saxenda approved in Europe for the treatment of obesity
Treatment with Saxenda reduced the risk of developing T2D
Saxenda (liraglutide) for the Treatment of Obesity - Clinical Trials Arena
Novo Nordisk: Make-And-Take Strategy For The Obesity Drug Market (NYSE:NVO) | Seeking Alpha
New England Journal of Medicine publishes phase 3 trial data demonstrating improvements in BMI and body weight in adolescents with obesity taking Saxenda®
Saxenda®
Novo Nordisk drags competitor to court over Saxenda copies — MedWatch
![Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States](https://photos.prnewswire.com/prnfull/20150421/200124LOGO "Novo Nordisk announces Saxenda® (liraglutide [rDNA origin] injection) is now commercially available in the United States")